Pharmacological inhibition of PORCN is highly selective for Wnt signalling and significantly inhibits the growth of Wnt-dependent tumours, highlighting its promise as a cancer therapy target (Liu et al., 2022). The gene discussed is PORCN; the disease is cancer.